IP Library › Granted Patent US 12,421,310
Granted Patent B2
US 12,421,310 · App. 17/041,100 · Granted Sep 23, 2025

CD47 binding agents

Inventor: William James Jonathan Finlay (Glasgow, GB)
Assignee: CENTESSA PHARMACEUTICALS (UK) LIMITED
C07K16/2803A61K45/06A61K47/6849A61K2039/505C07K2317/14C07K2317/24C07K2317/31C07K2317/565C07K2317/567C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,310
App. No.
17/041,100
Granted
Sep 23, 2025
Kind
B2
Abstract

Provided herein are antibody molecules that bind specifically to CD47 and related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

Claims (45)

1. An anti-CD47 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein

(a) the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNANTYLG (SEQ ID NO:55), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASHVPYT (SEQ ID NO:53);

(b) the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNGNTYLG (SEQ ID NO:51), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASHVPYT (SEQ ID NO:53);

(c) the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNAYNYLG (SEQ ID NO:56), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASHVPYT (SEQ ID NO:53);

(d) the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNAYNYLG (SEQ ID NO:56), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASQVPYT (SEQ ID NO:54);

(e) the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNANTYLG (SEQ ID NO:55), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASQVPYT (SEQ ID NO:54);

(f) the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNGNTYLG (SEQ ID NO:51), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASQVPYT (SEQ ID NO:54); or

(g) the VH region amino acid sequence comprises HCDR1 of GYSFTNYNIH (SEQ ID NO:57), HCDR2 of MGTIYPGNSDTSYNPSFQG (SEQ ID NO: 61) and HCDR3 of GGVRAMDY (SEQ ID NO:62); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNGNTYLG (SEQ ID NO:51), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of MQASQVPYT (SEQ ID NO:63).

2. The antibody or antigen-binding portion of claim 1 , wherein

(a) the VH region amino acid sequence comprises SEQ ID NO: 1 and the VL region amino acid sequence comprises SEQ ID NO:2;

(b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:4;

(c) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6;

(d) the VH region amino acid sequence comprises SEQ ID NO:7 and the VL region amino acid sequence comprises SEQ ID NO:8;

(e) the VH region amino acid sequence comprises SEQ ID NO:9 and the VL region amino acid sequence comprises SEQ ID NO: 10;

(f) the VH region amino acid sequence comprises SEQ ID NO: 11 and the VL region amino acid sequence comprises SEQ ID NO: 12;

(g) the VH region amino acid sequence comprises SEQ ID NO: 13 and the VL region amino acid sequence comprises SEQ ID NO: 14; or

(h) the VH region amino acid sequence comprises SEQ ID NO:15 and the VL region amino acid sequence comprises SEQ ID NO: 16.

3. The antibody or antigen-binding portion of claim 1 , wherein the antibody is humanized or chimeric.

4. The antibody or antigen-binding portion of claim 1 , wherein the VH region, the VL region, or both the VH and the VL region comprise one or more human framework region amino acid sequences.

5. The antibody or antigen-binding portion of claim 1 , wherein the VH region, the VL region, or both the VH and the VL region comprise a human variable region framework scaffold amino acid sequence into which the CDRs have been inserted.

6. The antibody or antigen-binding portion of claim 1 , wherein the VH region comprises an IGHV5-51 or IGHV1-3 human germline scaffold amino acid sequence into which the HCDR1, HCDR2 and HCDR3 amino acid sequences have been inserted.

7. The antibody or antigen-binding portion of claim 1 , wherein the VL region comprises an IGKV2-28 human germline scaffold amino acid sequence into which the LCDR1, LCDR2 and LCDR3 amino acid sequences have been inserted.

8. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion comprises an immunoglobulin constant region.

9. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region is IgG, IgE, IgM, IgD, IgA or IgY.

10. The antibody or antigen-binding portion of claim 9 , wherein the immunoglobulin constant region is IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2.

11. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region is a wild-type human IgG4 constant region, a human IgG4 constant region comprising the amino acid substitution S228P, a wild-type human IgG1 constant region, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A and G237A or a wild-type human IgG2 constant region.

12. The antibody or antigen-binding portion of claim 8 , wherein the immunoglobulin constant region comprises any one of SEQ ID NOS:17-23.

13. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is an Fab, an Fab′, an F(ab′)2, an Fv, an scFv, a maxibody, a minibody, an intrabody, a diabody, a triabody, a tetrabody, or a bis-scFv.

14. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is monoclonal.

15. The antibody or antigen-binding portion of claim 1 , wherein the antibody or antigen-binding portion is tetrameric, tetravalent or multispecific.

16. An immunoconjugate comprising the antibody or antigen-binding portion of claim 1 , linked to a therapeutic agent.

17. A pharmaceutical composition comprising the antibody or antigen-binding portion of claim 1 and a pharmaceutically acceptable carrier.

18. A nucleic acid molecule encoding both the VH and the VL region amino acid sequences of the antibody or antigen-binding portion of claim 1 .

19. An expression vector comprising the nucleic acid molecule of claim 18 .

20. An individual recombinant host cell comprising the nucleic acid molecule of claim 18 .

21. A method of producing an anti-CD47 antibody or an antigen-binding portion thereof, the method comprising:

culturing the recombinant host cell of claim 20 under conditions whereby the nucleic acid molecule is expressed, thereby producing the antibody or antigen-binding portion; and

isolating the antibody or antigen-binding portion from the host cell or culture.

22. A method for enhancing an immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding portion of claim 1 , thereby enhancing the immune response.

23. The method of claim 22 , wherein the subject has a cancer, an autoimmune disease, an inflammatory disease, a cardiovascular disease or a fibrotic disease.

24. The method of claim 23 , wherein the cancer is gastrointestinal stromal cancer (GIST), pancreatic cancer, melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma or cancer of hematological tissues.

25. The method of claim 23 , wherein the autoimmune disease or the inflammatory disease is arthritis, asthma, multiple sclerosis, psoriasis, Crohn's disease, inflammatory bowel disease, lupus, Grave's disease, Hashimoto's thyroiditis or ankylosing spondylitis.

26. The method of claim 23 , wherein the cardiovascular disease is coronary heart disease or atherosclerosis.

27. The method of claim 23 , wherein the fibrotic disease is myocardial infarction, angina, osteoarthritis, pulmonary fibrosis, cystic fibrosis, bronchitis or asthma.

28. An anti-CD47 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region amino acid sequence comprises HCDR1 of GYTFTNYAMH (SEQ ID NO:48), HCDR2 of MGTIYPGNDDTKYNQKFQG (SEQ ID NO:49) and HCDR3 of GGFRAMDY (SEQ ID NO:50); and the VL region amino acid sequence comprises LCDR1 of RSSQSLLHSNANTYLG (SEQ ID NO:55), LCDR2 of KGSNRFS (SEQ ID NO:52) and LCDR3 of FQASHVPYT (SEQ ID NO:53).

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2026
From: OXFORD FINANCE LLC
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 075069/0879 →
SECURITY INTEREST Recorded Dec 31, 2024
From: CENTESSA PHARMACEUTICALS (UK) LIMITED
To: OXFORD FINANCE LLC
Reel/Frame 069708/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2023
From: ULTRAHUMAN TWO LIMITED
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 065058/0045 →
CHANGE OF REGISTERED OFFICE ADDRESS Recorded May 20, 2022
From: ULTRAHUMAN TWO LIMITED
To: ULTRAHUMAN TWO LIMITED
Reel/Frame 060135/0770 →
SECURITY INTEREST Recorded Oct 4, 2021
From: APCINTEX LIMITED; JANPIX LIMITED; CAPELLA BIOSCIENCE LTD; LOCKBODY THERAPEUTICS LTD; ULTRAHUMAN TWO LIMITED; ULTRAHUMAN FOUR LIMITED; MORPHOGEN-IX LIMITED; OREXIA THERAPEUTICS LIMITED; CARDIOKINE BIOPHARMA LLC; PALLADIO BIOSCIENCES, INC.; PEARLRIVER BIO GMBH; Z FACTOR LIMITED
To: COCOON SA LLC
Reel/Frame 057710/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2020
From: FINLAY, WILLIAM JAMES JONATHAN
To: ULTRAHUMAN TWO LIMITED
Reel/Frame 053913/0676 →
Priority Claims (2)
GB 1804860 · Mar 27, 2018 · national
GB 1813693 · Aug 22, 2018 · national
Continuity (1)
Related Publication 20210179711A1 · Jun 17, 2021
References Cited (98)
US 9158117B2 · Li et al. · 2015 [cited by applicant]
US 9221908B2 · Frazier et al. · 2015 [cited by applicant]
US 9518117B2 · Frazier et al. · 2016 [cited by applicant]
US 10259873B2 · Frazier et al. · 2019 [cited by applicant]
US 10683350B2 · Finlay et al. · 2020 [cited by applicant]
US 11370840B2 · Finlay · 2022 [cited by applicant]
US 20140140989A1 · Eckelman et al. · 2014 [cited by applicant]
US 20170073395A1 · Finlay et al. · 2017 [cited by applicant]
US 20200277375A1 · Finlay et al. · 2020 [cited by applicant]
US 20220332819A1 · Finlay · 2022 [cited by applicant]
KR 20060121150A · 2006 [cited by applicant]
WO WO2008083949A2 · 2008 [cited by applicant]
WO WO2011143624A2 · 2011 [cited by examiner]
WO WO2013119714A1 · 2013 [cited by applicant]
WO WO2014093678A2 · 2014 [cited by applicant]
WO WO2015191861A1 · 2015 [cited by applicant]
WO WO2016081423A1 · 2016 [cited by applicant]
WO WO2016109415A1 · 2016 [cited by applicant]
WO WO2017049251A2 · 2017 [cited by applicant]
WO WO2017053423A1 · 2017 [cited by applicant]
WO WO2017121771A1 · 2017 [cited by applicant]
WO WO2017181033A1 · 2017 [cited by applicant]
WO WO2019034895A1 · 2019 [cited by applicant]
WO WO2019185717A1 · 2019 [cited by applicant]
Lazar et al. Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities. Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988). [cited by examiner]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L… [cited by examiner]
Brown et al., J Immunol. May 1996;156(9):3285-91 (Year: 1996). [cited by examiner]
Warzocha et al., Leukemia and Lymphoma (1997) vol. 24. pp. 267-281 (Year: 1997). [cited by examiner]
Greenspan et al. 1999 Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999). [cited by examiner]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 2000, 10:398-400 (Year: 2000). [cited by examiner]
Skolnick et al., Trends Biotechnol. Jan. 2000; 18(1):34-9 (Year: 2000). [cited by examiner]
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28 at 416 (Year: 2002). [cited by examiner]
Aagaard et al., Advanced Drug Delivery Reviews 59 (2007) 75-86 (Year: 2007). [cited by examiner]
Guido et al., Curr Med Chem. 2008; 15(1):37-46 (Year: 2008). [cited by examiner]
Mckeague et al., J Nucleic Acids. 2012;2012:748913. Epub Oct. 2, 20124 (Year: 2012). [cited by examiner]
Clark et al., J. Med. Chem., 2014, 57 (12), pp. 5023-5038 (Year: 2014). [cited by examiner]
Miosge, Proc Natl Acad Sci U S A. Sep. 15, 2015;112(37):E5189-98 (Year: 2015). [cited by examiner]
Kulmanov et al., Bioinformatics, 34(4), 2018, 660-668 (Year: 2018). [cited by examiner]
International Search Report and Written Opinion mailed Dec. 17, 2018 for International Application No. PCT/GB2018/052347, 19 pages. [cited by applicant]
UKIPO Search Report dated May 23, 2018 for GB Application No. GB1713298.6, 1 page. [cited by applicant]
International Search Report and Written Opinion mailed Jul. 18, 2019 for International Application No. PCT/EP2019/057723, 19 pages. [cited by applicant]
Ahmadi, M. et al., “Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics,” Pharm Res, 32:1383 (2005); https://doi.org/10.1007/s11095-014-1541-x, 12 pages. [cited by applicant]
Almagro, J. C. & Fransson, J., “Humanization of antibodies,” Frontiers in Bioscience, 13:1619-1633 (2008). [cited by applicant]
Bagshawe, K. D. et al., “Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites,” Antibody, Immunoconjugates, and Radiopharmaceuticals, 4(4):915-922 (1991). [cited by applicant]
Casipit, C. L. et al., “Improving the binding affinity of an antibody using molecular modeling and site-directed mutagenesis,” Protein Science, 7:1671-1680 (1998). [cited by applicant]
Chien, N. C. et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism,” Proc. Natl. Acad. Sci. USA, 86:5532-5536 (1989). [cited by applicant]
Fennell, B. J. et al., “CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery,” mAbs, 5(6):882-895 (2013). [cited by applicant]
Finlay, W. J. et al., “Affinity Maturation of a Humanized Rat Antibody for Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals a High Level of Mutational Plasticity Both Inside and Outside the Complementarity-Determini… [cited by applicant]
Finlay, W. J. J. et al., “Optimized Generation of High-Affinity, High-Specificity Single-Chain Fv Antibodies from Multiantigen Immunized Chickens,” Dermot Walls and Sinéad T. Loughran (eds.), Protein Chromatography: Met… [cited by applicant]
Glockshuber, R. et al., “Mapping and Modification of an Antibody Hapten Binding Site: A Site-Directed Mutagenesis Study of McP603,” Biochemistry, 30:3049-3054 (1991). [cited by applicant]
Harding, F. A. et al., “The immunogenicity of humanized and fully human antibodies. Residual immunogenicity resides in the CDR regions,” mAbs, 2(3):256-265 (2010). [cited by applicant]
Henikoff, S. & Henikoff, J. G., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci. USA, 89:10915-10919 (1992). [cited by applicant]
Holliger, P. & Hudson, P. J., “Engineered antibody fragments and the rise of single domains,” Nature Biotechnology, 23(9):1126-1136 (2005). [cited by applicant]
Hwang, W. Y. K. & Foote, J., “Immunogenicity of engineered antibodies,” Methods, 36:3-10 (2005). [cited by applicant]
Jones, P. T. et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 321:522-525 (1986). [cited by applicant]
Kobayashi, H. et al., “Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody,” Protein Engineering, 12(10):879-884 (1999). [cited by applicant]
Kobrin, B. J. et al., “A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding,” J Immunol., 146:2017-2020 (1991). [cited by applicant]
Ledermann, J. A. et al., “A Phase-I Study of Repeated Therapy with Radiolabelled Antibody to Carcinoembryonic Antigen Using Intermittent or Continuous Administration of Cyclosporin A to Suppress the Immune Response,” In… [cited by applicant]
Melero, I. et al., “Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells,” Clin Cancer Res, 19(5):1044-1053 (2013), and Correction, p. 1913. [cited by applicant]
Mouquet, H. et al., “Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation,” Nature, 467(7315):591-595 (2010); doi:10.1038/nature09385. [cited by applicant]
Nelson, A. L. et al., “Development trends for human monoclonal antibody therapeutics,” Nature Reviews Drug Discovery, 9:767-774 (2010). [cited by applicant]
North, B. et al., “A New Clustering of Antibody CDR Loop Conformations,” J. Mol. Biol. (2010); doi:10.1016/j.jmb.2010.10.030, 29 pages. [cited by applicant]
Panka, D. J. et al., Defining the structural correlates responsible for loss of arsonate affinity in an Id [cited by applicant]
Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982). [cited by applicant]
Schildbach, J. F. et al., “Modulation of antibody affinity by a non-contact residue,” Protein Science, 2:206-214 (1993). [cited by applicant]
Swindells, M. B. et al., “abYsis: Integrated Antibody Sequence and Structure-Management, Analysis, and Prediction,” J. Mol. Biol., 429:356-364 (2017). [cited by applicant]
Tiller, T et al., “A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties,” mAbs, 5(3):1-26 (2013). [cited by applicant]
Townsend, S. et al., “Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies,” PNAS, 112(50):15354-15359 (2015). [cited by applicant]
Tu, C. et al., “Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (ScFv),” The Journal of Biological C… [cited by applicant]
Van Aerts, L. Agjm et al., “Biosimilars entering the clinic without animal studies,” mAbs, 6(5):1155-1162 (2014). [cited by applicant]
Van Meer, P. J. K. et al., “Immunogenicity of mAbs in non-human primates during nonclinical safety assessment,” mAbs, 5(5):810-816 (2013). [cited by applicant]
Winkler, K. et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J Immunol, 165:4505-4514 (2000). [cited by applicant]
Zhou, F. et al., “A general user interface for prediction servers of proteins' post-translational modification sites,” Nature Protocols, 1(3): 1318-1321 (2006). [cited by applicant]
Yarilin, A. A. et al., Fundamentals of Immunology, p. 171 and p. 172-173 (1999), with English translation, 8 pages. [cited by applicant]
Yu, J. and M.F. Lin (Apr. 2005) Anti-CD47 monoclonal antibody (B6H12) impairs the maturation and function of human dendritic cells, J Exp Hematol (Zhongguo Shi Yan Xue Ye Xue Za Zhi), 13(2):192-197. English Abstract onl… [cited by applicant]
Bork, et al., Go hunting in sequence databases but watch out for the traps. Trends in Genetics 1996; 12:425-427. [cited by applicant]
Bork, P., Powers and pitfalls in Sequence analysis: The 70% hurdle. Genome Research 2000; 10:398-400. [cited by applicant]
BRENNER: Errors in genome annotation. Trends in Genetics. 15:132-133 (1999). [cited by applicant]
Doerks et al.: Protein annotation: detective work for function prediction. Trends in Genetics. 14:248-250 (1998). [cited by applicant]
Paul, W.E. Fundamental Immunology, Third Edition (textbook). “Fv Structure and Diversity in Three Dimensions” pp. 292-295; Raven Press, New York (1993). [cited by applicant]
Sela-Culang et al. The structural basis of antibody-antigen recognition. Front Immunol. 4:302 (2013). [cited by applicant]
Skolnick et al.: From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-39 (2000). [cited by applicant]
Smith et al.: The challenges of genome sequence annotation or “the devil is in the details”. Nature Biotechnol. 15:1222-1223 (1997). [cited by applicant]
Gokarn, Yatin R. et al. Self-buffering antibody formulations. Journal of pharmaceutical sciences 97(8):3051-3066 (2008). [cited by applicant]
MacCallum, Robert M. et al. Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
U.S. Appl. No. 16/543,884, filed Aug. 19, 2029, inventor William James Jonathan Finlay; Non-Final Office Action dated Dec. 9, 2019, 10 pages. [cited by applicant]
U.S. Appl. No. 16/543,884, filed Aug. 19, 2029, inventor William James Jonathan Finlay; Notice of Allowance dated Apr. 7, 2020, 7 pages. [cited by applicant]
U.S. Appl. No. 16/877,938, filed May 17, 2020, inventor William James Jonathan Finlay; Notice of Allowance dated Feb. 18, 2022, 10 pages. [cited by applicant]
U.S. Appl. No. 17/849,101, filed Jun. 24, 2022, inventor William James Jonathan Finlay; Office Action dated Jan. 17, 2024, 8 pages. [cited by applicant]
U.S. Appl. No. 17/849,101, filed Jun. 24, 2022, inventor William James Jonathan Finlay; Office Action dated Jun. 21, 2024, 10 pages. [cited by applicant]
Wang, Wei. et al. Antibody Structure, Instability, and Formulation. Journal of Pharmaceutical Sciences 96(1):1-26 (2007). [cited by applicant]
Hollevoet, Kevin, et al., State of Play and Clinical Prospects of Antibody Gene Transfer. Journal of Translational Medicine 15(1): 19 Pages (2017). [cited by applicant]
STROHL: Current progress in innovative engineered antibodies. Protein Cell. 9(1):86-120 (2018). [cited by applicant]
U.S. Appl. No. 16/543,884 Non-Final Office Action dated Dec. 9, 2019. [cited by applicant]
U.S. Appl. No. 16/543,884 Notice of Allowance dated Apr. 7, 2020. [cited by applicant]
U.S. Appl. No. 16/877,938 Notice of Allowance dated Feb. 18, 2022. [cited by applicant]
U.S. Apppl. No. 17/849,101 Office Action dated Jan. 17, 2024. [cited by applicant]
Van Hoecke, et al. How mRNA therapeutics are entering the monoclonal antibody field. J Transl Med. Feb. 22, 2019;17(1):54. doi: 10.1186/s12967-019-1804-8. [cited by applicant]